ADL Bionatur Solutions
ADL BIONATUR SOLUTIONS ENTERS INTO AN INITIAL EUR 13 MILLION STRATEGIC ALLIANCE WITH JAPANESE PHARMA COMPANY
DGAP-News: ADL Bionatur Solutions / Key word(s): Alliance ADL BIONATUR SOLUTIONS ENTERS INTO AN INITIAL EUR 13 MILLION STRATEGIC ALLIANCE WITH JAPANESE PHARMA COMPANY – Alliance reaffirms ADL as global supply partner of sterile active pharmaceutical ingredients León, Spain, 07 August 2019 – ADL Bionatur Solutions (MAB: ADL), a company specialized in research and development of health, cosmetic and beauty products, services and industrial fermentation production, announced today the signing of a strategic alliance with a new customer in Japan for active sterile pharmaceutical ingredients (APIs) production. The revenues of the contract with the undisclosed Manufacturer of pharmaceuticals, agricultural chemicals and veterinary drugs amounts to an initial amount of EUR 13 million over the next 5 years. “We are delighted to win a leading Japanese pharma company as a new customer for our API production. This 5-year partnership underlines our claim and commitment to high-quality APIs production in sterile conditions. ADL is broadening its customer base in Asia-Pacific ensuring access to the fast-growing market of this region,” said Pilar de la Huerta, CEO of ADL Bionatur Solutions. “The previously announced contract extensions and this new alliance keep us right on track for our strong financial guidance to achieve an overall positive EBITDA full year results as well as revenues between EUR 50 – 55 million.” ADL holds foreign manufacturer accreditations (FMA) from the PMDA (Pharmaceuticals and Medical Devices Agency of Japan) and MFDS (Ministry of Food and Drug Safety of South Korea), within others, and is an established partner for APIs production under sterile condition worldwide. About ADL Bionatur Solutions For more Information please contact: ADL Bionatur Solutions International Media & Investor Relations
07.08.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |